Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Stoke Therapeutics Analyst Ratings
Buy Rating Affirmed for Stoke Therapeutics Amid Strong Pipeline Prospects and Financial Stability
Canadian Investment Banking Group: Maintaining the Stoke Therapeutics (STOK.US) rating, adjusted from buy to buy rating, and adjusted the target price from $21.00 to $20.00.
Analysts Are Bullish on Top Healthcare Stocks: Stoke Therapeutics (STOK), Oric Pharmaceuticals (ORIC)
Stoke Therapeutics Analyst Ratings
Buy Rating for Stoke Therapeutics With Adjusted Price Target Amid Regulatory and Developmental Progress
Stoke Therapeutics Analyst Ratings
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Buy Rating Justified by Stoke Therapeutics' Promising Pipeline and Strategic Market Positioning
Needham: Reiterates Stoke Therapeutics (STOK.US) rating and adjusted from buy to buy rating, target price is $22.00.
Stoke Therapeutics Analyst Ratings
Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC (GB:HLN) and Stoke Therapeutics (STOK)
Stoke Therapeutics Analyst Ratings
Stoke Therapeutics' STK-001 Shows Promise: Buy Rating Affirmed Amid Positive Clinical and Financial Outlook
Wedbush Sticks to Their Buy Rating for Stoke Therapeutics (STOK)
Canaccord Genuity Adjusts Stoke Therapeutics Price Target to $21 From $18, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Elevance Health (ELV) and Stoke Therapeutics (STOK)
Stoke Therapeutics' STK-001 Shows Promising Results: A Strong Buy Rating With Increased Price Target